Multiple Retinal Artery Occlusions on Anticoagulation – What’s Next?
American Society of Retina Specialists (ASRS) posted on LinkedIn:
”How would you manage a patient with multiple branch retinal artery occlusions despite anticoagulation?
In a new episode of the JVRD Author’s Forum podcast, Dr. Albert Li of Vitreoretinal Consultants of New York joins host Tim Murray to discuss this challenging scenario, featured in the July/August 2025 issue of the Journal of VitreoRetinal Diseases.
Their conversation explores a remarkable case of triple-negative antiphospholipid syndrome in which the patient experienced successive retinal artery occlusions and later died from systemic complications. The discussion highlights:
- The limits of current anticoagulation therapies
- The role of fluorescein angiography and multimodal imaging in diagnosis
- Why urgent, multidisciplinary evaluation is essential for these patients
Watch on YouTube and explore even more episodes at www.ASRS.org/JVRDForum.”
Read the full article here.
Title: Multiple Successive Branch Retinal Artery Occlusions in a Patient With Antiphospholipid Syndrome Despite Anticoagulation
Authors: Samantha R. Goldburg, Albert S. Li

Stay updated with Hemostasis Today.
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria
-
Aug 10, 2026, 16:51Suebsarn Ruksakulpiwat։ A New Milestone in the Development of the Stroke Risk Screening Scales
-
Aug 10, 2026, 16:09Preetie Shetty Akkunje: Making Stroke Rehabilitation Accessible in Low-Resource Settings
-
Aug 10, 2026, 15:50The Next Antithrombotic Frontier: GPVI Inhibitors Beyond Aspirin